Genetically engineered mouse models (GEMM) of ovarian cancer effectively replicate the biological features and pathological processes of human ovarian cancer through precise gene editing. Alfa Cytology, with its dedicated team of researchers, is fully committed to advancing the research and development of these invaluable GEMM.
The GEMM of ovarian cancer is a sophisticated experimental animal model created using advanced gene editing technology to precisely mimic the biological features and pathological processes of human ovarian cancer. These models are typically genetically modified with specific alterations in key genes associated with ovarian cancer, such as KRAS, PIK3CA, and TP53, among others. Such genetic modifications enable the mice to naturally develop ovarian tumors in vivo, closely resembling the human disease.
Fig.1 Different strategies to manipulate the mouse genome. (BISWAS K, et al., 2023)
Alfa Cytology is committed to the research and development of genetically engineered mouse models of ovarian cancer to advance this field. We use advanced gene editing technologies to create efficient experimental models, offering researchers robust tools to investigate the pathogenesis and pathology of ovarian cancer.
Gene Editing and Model Construction
Using gene editing techniques, specific genes were targeted to create mouse models of ovarian cancer. These models were designed to accurately reflect the genetic background of human ovarian cancer.
Phenotypic Evaluation of the Model
A systematic phenotypic analysis was conducted on the constructed mouse models. This included assessing tumor growth rates, metastatic potential, and biomarker expression to verify the validity and stability of the models.
Pharmacodynamics Evaluation
GEMM of ovarian cancer can monitor tumor growth, metastasis, and survival post-drug administration. They also help analyze drug effects on the tumor microenvironment and immune system, and provide insights into drug mechanisms via histology and biomarker detection.
Genetically engineered mouse models of ovarian cancer primarily encompass the following types:
Knockout Mice: Our research team generated these models by knocking out specific genes associated with ovarian cancer. In this way, we can study the role of these genes in tumorigenesis.
Transgenic Mice: Oncogenes can be introduced into the mouse genome to induce ovarian cancer formation. This facilitates the study of tumor development and metastasis.
Case Study
Our advanced genetic engineering platform utilizes state-of-the-art gene editing and transgenic technologies to create bespoke models with defined genetic drivers. By introducing precise gain- or loss-of-function mutations into cell lines or mice, we deliver models with clear causal relationships for unequivocal target validation, drug resistance studies, and personalized therapy development.
Cell Line: ID8 cell lines
Age: 6-8 weeks
Species: C57BL/6 mice
Weight: 20-22 g
Fig. 2 Construction of genetically engineered ovarian cancer models
To investigate the specific roles of key tumor suppressors, we generated conditional knockout mutations of Trp53 and Brca2 within the ID8 murine ovarian epithelial cell line. This creates a genetically defined system to study tumorigenesis driven by these critical pathway losses.
For the mouse model, we longitudinally monitored the time of spontaneous ovarian tumor formation, incidence rate, growth kinetics, and survival period (Fig. 3). Concurrently, detailed histopathological evaluation of resulting tumors to confirm phenotype and disease pathology (Fig. 4).
Fig. 3 Survival analysis of genetically engineered ovarian cancer models
Fig. 4 Representative H&E staining of tumor tissues
Alfa Cytology has garnered extensive experience over many years in researching genetically engineered mouse models of ovarian cancer. Leveraging advanced gene editing technologies, our expert team has successfully developed a variety of mouse models to support diverse research projects. Should you have any questions about our services or require additional information, please do not hesitate to contact us.
Reference
For research use only.
Alfa Cytology, located in New York, specializes in preclinical research solutions to support ovarian cancer therapy development, offering a streamlined process from target discovery to IND application.
Copyright © 2026 Alfa Cytology. All rights reserved.
